NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
Today, we’re seeing significant scientific breakthroughs that are revolutionizing the treatment of challenging conditions like cancers and both rare and chronic diseases. Advances that activate the immune system or retool genes with a single treatment to change the course of disease all signal that personalized medicine is here and continuing to evolve.
These amazing and important innovations can mean better outcomes for patients. But scientific innovation alone is not enough. To make sure that these promising treatments are delivering the best outcomes for patients, we need innovative thinking about the business of health care as well.
How can health system stakeholders kickstart new thinking and novel approaches that will help align administrative and business processes with medical and digital innovations? How can we develop systems that ensure patents have access to increasingly individualized treatments while sustaining the development of more advanced breakthroughs?
National Pharmaceutical Council (NPC) President Dan Leonard tackles these questions in his latest commentary for Chain Drug Review. In it, he explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more.